Serum Soluble Receptors for Advanced Glycation End-Products May Predict Mortality in Microscopic Polyangiitis and Granulomatosis with Polyangiitis
This study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE) and the soluble form of RAGE (sRAGE) measured at diagnosis are associated with all-cause mortality in patients with microscopic polyangiitis (MPA) a...
Saved in:
Published in | Yonsei medical journal Vol. 65; no. 11; pp. 651 - 660 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
Yonsei University College of Medicine
01.11.2024
연세대학교의과대학 |
Subjects | |
Online Access | Get full text |
ISSN | 0513-5796 1976-2437 1976-2437 |
DOI | 10.3349/ymj.2023.0466 |
Cover
Abstract | This study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE) and the soluble form of RAGE (sRAGE) measured at diagnosis are associated with all-cause mortality in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA).
Serum EN-RAGE and sRAGE were measured in 75 immunosuppressive drug-naïve MPA and GPA patients using an immunoassay, with their clinical and laboratory data reviewed. The optimal cut-off point of EN-RAGE and sRAGE was calculated by finding the threshold with the maximum sum of sensitivity and specificity. In addition, the least absolute shrinkage and selection operator regression was adopted to select variables included in the multivariable Cox proportional hazards (PH) regression model.
The median age of the patients was 67.0 years, and 34% were male. Neither serum EN-RAGE nor sRAGE at diagnosis was correlated with the Birmingham Vasculitis Activity Score. Furthermore, no correlation was observed between serum EN-RAGE and sRAGE. Deceased patients had significantly lower serum EN-RAGE and higher serum sRAGE at diagnosis compared to surviving patients. Patients with serum EN-RAGE at diagnosis ≤84.37 ng/mL and serum sRAGE at diagnosis ≥1.82 ng/mL showed significantly lower survival probabilities compared to those without. In multivariable Cox PH regression model, only serum sRAGE at diagnosis ≥1.82 ng/mL, rather than serum EN-RAGE at diagnosis ≤84.37 ng/mL, was independently associated with all-cause mortality (hazard ratio 7.094).
This study is the first to demonstrate that serum sRAGE at diagnosis may independently predict all-cause mortality during follow-up in patients with MPA and GPA. |
---|---|
AbstractList | This study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE) and the soluble form of RAGE (sRAGE) measured at diagnosis are associated with all-cause mortality in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA).PURPOSEThis study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE) and the soluble form of RAGE (sRAGE) measured at diagnosis are associated with all-cause mortality in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA).Serum EN-RAGE and sRAGE were measured in 75 immunosuppressive drug-naïve MPA and GPA patients using an immunoassay, with their clinical and laboratory data reviewed. The optimal cut-off point of EN-RAGE and sRAGE was calculated by finding the threshold with the maximum sum of sensitivity and specificity. In addition, the least absolute shrinkage and selection operator regression was adopted to select variables included in the multivariable Cox proportional hazards (PH) regression model.MATERIALS AND METHODSSerum EN-RAGE and sRAGE were measured in 75 immunosuppressive drug-naïve MPA and GPA patients using an immunoassay, with their clinical and laboratory data reviewed. The optimal cut-off point of EN-RAGE and sRAGE was calculated by finding the threshold with the maximum sum of sensitivity and specificity. In addition, the least absolute shrinkage and selection operator regression was adopted to select variables included in the multivariable Cox proportional hazards (PH) regression model.The median age of the patients was 67.0 years, and 34% were male. Neither serum EN-RAGE nor sRAGE at diagnosis was correlated with the Birmingham Vasculitis Activity Score. Furthermore, no correlation was observed between serum EN-RAGE and sRAGE. Deceased patients had significantly lower serum EN-RAGE and higher serum sRAGE at diagnosis compared to surviving patients. Patients with serum EN-RAGE at diagnosis ≤84.37 ng/mL and serum sRAGE at diagnosis ≥1.82 ng/mL showed significantly lower survival probabilities compared to those without. In multivariable Cox PH regression model, only serum sRAGE at diagnosis ≥1.82 ng/mL, rather than serum EN-RAGE at diagnosis ≤84.37 ng/mL, was independently associated with all-cause mortality (hazard ratio 7.094).RESULTSThe median age of the patients was 67.0 years, and 34% were male. Neither serum EN-RAGE nor sRAGE at diagnosis was correlated with the Birmingham Vasculitis Activity Score. Furthermore, no correlation was observed between serum EN-RAGE and sRAGE. Deceased patients had significantly lower serum EN-RAGE and higher serum sRAGE at diagnosis compared to surviving patients. Patients with serum EN-RAGE at diagnosis ≤84.37 ng/mL and serum sRAGE at diagnosis ≥1.82 ng/mL showed significantly lower survival probabilities compared to those without. In multivariable Cox PH regression model, only serum sRAGE at diagnosis ≥1.82 ng/mL, rather than serum EN-RAGE at diagnosis ≤84.37 ng/mL, was independently associated with all-cause mortality (hazard ratio 7.094).This study is the first to demonstrate that serum sRAGE at diagnosis may independently predict all-cause mortality during follow-up in patients with MPA and GPA.CONCLUSIONThis study is the first to demonstrate that serum sRAGE at diagnosis may independently predict all-cause mortality during follow-up in patients with MPA and GPA. This study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE) and the soluble form of RAGE (sRAGE) measured at diagnosis are associated with all-cause mortality in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Serum EN-RAGE and sRAGE were measured in 75 immunosuppressive drug-naïve MPA and GPA patients using an immunoassay, with their clinical and laboratory data reviewed. The optimal cut-off point of EN-RAGE and sRAGE was calculated by finding the threshold with the maximum sum of sensitivity and specificity. In addition, the least absolute shrinkage and selection operator regression was adopted to select variables included in the multivariable Cox proportional hazards (PH) regression model. The median age of the patients was 67.0 years, and 34% were male. Neither serum EN-RAGE nor sRAGE at diagnosis was correlated with the Birmingham Vasculitis Activity Score. Furthermore, no correlation was observed between serum EN-RAGE and sRAGE. Deceased patients had significantly lower serum EN-RAGE and higher serum sRAGE at diagnosis compared to surviving patients. Patients with serum EN-RAGE at diagnosis ≤84.37 ng/mL and serum sRAGE at diagnosis ≥1.82 ng/mL showed significantly lower survival probabilities compared to those without. In multivariable Cox PH regression model, only serum sRAGE at diagnosis ≥1.82 ng/mL, rather than serum EN-RAGE at diagnosis ≤84.37 ng/mL, was independently associated with all-cause mortality (hazard ratio 7.094). This study is the first to demonstrate that serum sRAGE at diagnosis may independently predict all-cause mortality during follow-up in patients with MPA and GPA. Purpose: This study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE) and the soluble form of RAGE (sRAGE) measured at diagnosis are associated with all-cause mortality in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Materials and Methods: Serum EN-RAGE and sRAGE were measured in 75 immunosuppressive drug-naïve MPA and GPA patients using an immunoassay, with their clinical and laboratory data reviewed. The optimal cut-off point of EN-RAGE and sRAGE was calculated by finding the threshold with the maximum sum of sensitivity and specificity. In addition, the least absolute shrinkage and selection operator regression was adopted to select variables included in the multivariable Cox proportional hazards (PH) regression model. Results: The median age of the patients was 67.0 years, and 34% were male. Neither serum EN-RAGE nor sRAGE at diagnosis was correlated with the Birmingham Vasculitis Activity Score. Furthermore, no correlation was observed between serum EN-RAGE and sRAGE. Deceased patients had significantly lower serum EN-RAGE and higher serum sRAGE at diagnosis compared to surviving patients. Patients with serum EN-RAGE at diagnosis ≤84.37 ng/mL and serum sRAGE at diagnosis ≥1.82 ng/mL showed significantly lower survival probabilities compared to those without. In multivariable Cox PH regression model, only serum sRAGE at diagnosis ≥1.82 ng/mL, rather than serum EN-RAGE at diagnosis ≤84.37 ng/mL, was independently associated with all-cause mortality (hazard ratio 7.094). Conclusion: This study is the first to demonstrate that serum sRAGE at diagnosis may independently predict all-cause mortality during follow-up in patients with MPA and GPA. KCI Citation Count: 0 |
Author | Yoon, Taejun Ahn, Sung Soo Park, Yong-Beom Lee, Sang-Won Ha, Jang Woo Ko, Eunhee Song, Jason Jungsik |
AuthorAffiliation | 4 Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea 3 Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea 1 Department of Medical Science, BK21 Plus Project, Yonsei University College of Medicine, Seoul, Korea 2 Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea |
AuthorAffiliation_xml | – name: 2 Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea – name: 4 Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea – name: 3 Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea – name: 1 Department of Medical Science, BK21 Plus Project, Yonsei University College of Medicine, Seoul, Korea |
Author_xml | – sequence: 1 givenname: Taejun orcidid: 0000-0003-2147-3555 surname: Yoon fullname: Yoon, Taejun organization: Department of Medical Science, BK21 Plus Project, Yonsei University College of Medicine, Seoul, Korea – sequence: 2 givenname: Sung Soo orcidid: 0000-0002-9002-9880 surname: Ahn fullname: Ahn, Sung Soo organization: Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea – sequence: 3 givenname: Jang Woo orcidid: 0000-0002-3307-5215 surname: Ha fullname: Ha, Jang Woo organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea – sequence: 4 givenname: Eunhee orcidid: 0009-0002-6528-0069 surname: Ko fullname: Ko, Eunhee organization: Department of Medical Science, BK21 Plus Project, Yonsei University College of Medicine, Seoul, Korea – sequence: 5 givenname: Jason Jungsik orcidid: 0000-0003-0662-7704 surname: Song fullname: Song, Jason Jungsik organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea., Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea – sequence: 6 givenname: Yong-Beom orcidid: 0000-0003-4695-8620 surname: Park fullname: Park, Yong-Beom organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea., Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea – sequence: 7 givenname: Sang-Won orcidid: 0000-0002-8038-3341 surname: Lee fullname: Lee, Sang-Won organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea., Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39439169$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003129791$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNpVkl1LHDEUhkOx1I_2srcll0WYbb5mxlyVRawVXLqovQ6ZzBmNZpJtkrHM3-gvbta1UiFwSPLkOZDzHqI9Hzwg9JGSBedCfpnH-wUjjC-IaJo36IDKtqmY4O0eOiA15VXdymYfHaZ0TwhrKWHv0D6XgkvayAP05xriNOLr4KbOAb4CA5scYsJDiHjZP2pvoMfnbjY62-Dxme-rdQz9ZHLCKz3jdYTemoxXIWbtbJ6x9XhlTQzJhI01eB3crP2ttdkmrH2RRe0nF0adQypHv22-ewW9R28H7RJ8eK5H6Oe3s5vT79Xlj_OL0-VlZXgrc0V7Q7tWtA3vNDsxhncMTK3LHiSTZfWsA6qFgJp3raai0YQZ0nA9yKEG4EfoeOf1cVAPxqqg7VO9DeohquXVzYWihT-pG1Hgrzt4M3Uj9AZ8jtqpTbSjjvPT09c33t4V0aOitKaScloMn58NMfyaIGU12mTAOe0hTElxWkbHaipkQT_93-yly7-xFaDaAdtvThGGF4QStY2FKrFQ21iobSz4X0NmrmA |
Cites_doi | 10.1097/MD.0b013e318205a4c6 10.1002/jemt.10300 10.1136/annrheumdis-2021-221795 10.1136/annrheumdis-2021-221796 10.1136/annrheumdis-2016-210942 10.1155/2019/2067353 10.1080/14397595.2018.1551107 10.1093/rheumatology/keab413 10.1186/s12865-022-00513-4 10.1016/j.crohns.2011.03.011 10.3349/ymj.2019.60.1.10 10.1002/art.22217 10.3389/fimmu.2022.931473 10.1016/j.vph.2015.06.011 10.1093/advances/nmab072 10.1001/jama.2013.13805 10.3349/ymj.2022.0435 10.1002/lt.24129 10.1136/ard.2006.054593 10.1136/ard.2008.101279 10.1373/clinchem.2016.264135 10.3390/molecules27154922 10.1186/s12891-015-0569-3 10.1016/j.bbagen.2016.11.040 10.5114/reum.2017.71638 10.1189/jlb.1012519 10.1002/art.37715 10.1016/j.redox.2021.101958 10.1186/1478-811X-7-12 10.1136/annrheumdis-2013-203255 10.3349/ymj.2021.62.4.279 |
ContentType | Journal Article |
Copyright | Copyright: Yonsei University College of Medicine 2024. Copyright: Yonsei University College of Medicine 2024 2024 Yonsei University College of Medicine |
Copyright_xml | – notice: Copyright: Yonsei University College of Medicine 2024. – notice: Copyright: Yonsei University College of Medicine 2024 2024 Yonsei University College of Medicine |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
DOI | 10.3349/ymj.2023.0466 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1976-2437 |
EndPage | 660 |
ExternalDocumentID | oai_kci_go_kr_ARTI_10638564 PMC11519131 39439169 10_3349_ymj_2023_0466 |
Genre | Journal Article |
GrantInformation_xml | – fundername: CELLTRION PHARM, Inc. grantid: NCR 2019-6 – fundername: Chong Kun Dang Pharmaceutical Corp – fundername: ; – fundername: ; grantid: NCR 2019-6 |
GroupedDBID | --- .55 .GJ 123 29R 2WC 36B 5-W 53G 5RE 8JR 8XY 9ZL AAYXX ACYCR ADBBV ADRAZ AEGXH AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION CS3 DIK DU5 E3Z EBD EF. EMB EMOBN F5P GROUPED_DOAJ GX1 HYE KQ8 L7B M48 MK0 O5R O5S OK1 OVT P2P PGMZT RNS RPM SV3 TR2 X7M XSB ZGI ZXP CGR CUY CVF ECM EIF M~E NPM 7X8 5PM |
ID | FETCH-LOGICAL-c379t-1dc1b74763ba28cc3b2ec5a763e929929d2be1a44e53b7a146a02c063af9f5ee3 |
IEDL.DBID | M48 |
ISSN | 0513-5796 1976-2437 |
IngestDate | Sat Oct 26 03:19:14 EDT 2024 Thu Aug 21 18:44:00 EDT 2025 Fri Jul 11 16:55:00 EDT 2025 Thu Jan 02 22:24:17 EST 2025 Tue Jul 01 04:03:32 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | granulomatosis with polyangiitis mortality Soluble microscopic polyangiitis receptors for advanced glycation end products |
Language | English |
License | Copyright: Yonsei University College of Medicine 2024. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c379t-1dc1b74763ba28cc3b2ec5a763e929929d2be1a44e53b7a146a02c063af9f5ee3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Taejun Yoon and Sung Soo Ahn contributed equally to this work. https://www.eymj.org/DOIx.php?id=10.3349/ymj.2023.0466 |
ORCID | 0009-0002-6528-0069 0000-0003-4695-8620 0000-0002-9002-9880 0000-0003-0662-7704 0000-0002-8038-3341 0000-0002-3307-5215 0000-0003-2147-3555 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3349/ymj.2023.0466 |
PMID | 39439169 |
PQID | 3119725149 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_10638564 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11519131 proquest_miscellaneous_3119725149 pubmed_primary_39439169 crossref_primary_10_3349_ymj_2023_0466 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-11-01 |
PublicationDateYYYYMMDD | 2024-11-01 |
PublicationDate_xml | – month: 11 year: 2024 text: 2024-11-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Yonsei medical journal |
PublicationTitleAlternate | Yonsei Med J |
PublicationYear | 2024 |
Publisher | Yonsei University College of Medicine 연세대학교의과대학 |
Publisher_xml | – name: Yonsei University College of Medicine – name: 연세대학교의과대학 |
References | Mukhtyar (10.3349/ymj.2023.0466_ref16) 2009; 68 Yilmaz (10.3349/ymj.2023.0466_ref19) 2011; 5 Tan (10.3349/ymj.2023.0466_ref26) 2017; 76 Masiak (10.3349/ymj.2023.0466_ref5) 2017; 55 Moroz (10.3349/ymj.2023.0466_ref10) 2003; 60 Serveaux-Dancer (10.3349/ymj.2023.0466_ref21) 2019; 2019 Antonelli (10.3349/ymj.2023.0466_ref29) 2017; 1861 Ahn (10.3349/ymj.2023.0466_ref14) 2021; 62 Pyo (10.3349/ymj.2023.0466_ref15) 2023; 64 Pullerits (10.3349/ymj.2023.0466_ref28) 2006; 54 Sharifi-Zahabi (10.3349/ymj.2023.0466_ref30) 2021; 12 Bai (10.3349/ymj.2023.0466_ref12) 2022; 23 Millet (10.3349/ymj.2023.0466_ref6) 2013; 72 Jafari Nakhjavani (10.3349/ymj.2023.0466_ref18) 2019; 29 Jennette (10.3349/ymj.2023.0466_ref1) 2013; 65 Page (10.3349/ymj.2023.0466_ref11) 2022; 61 Chen (10.3349/ymj.2023.0466_ref20) 2015; 16 Kierdorf (10.3349/ymj.2023.0466_ref31) 2013; 94 Yue (10.3349/ymj.2023.0466_ref7) 2022; 27 Dong (10.3349/ymj.2023.0466_ref9) 2022; 13 Schmidt (10.3349/ymj.2023.0466_ref23) 2015; 72 Riehl (10.3349/ymj.2023.0466_ref8) 2009; 7 Choi (10.3349/ymj.2023.0466_ref27) 2019; 60 Guillevin (10.3349/ymj.2023.0466_ref17) 2011; 90 Basta (10.3349/ymj.2023.0466_ref24) 2015; 21 Murray (10.3349/ymj.2023.0466_ref25) 2013; 310 Suppiah (10.3349/ymj.2023.0466_ref4) 2022; 81 Loomis (10.3349/ymj.2023.0466_ref22) 2017; 63 Watts (10.3349/ymj.2023.0466_ref2) 2007; 66 Robson (10.3349/ymj.2023.0466_ref3) 2022; 81 Erusalimsky (10.3349/ymj.2023.0466_ref13) 2021; 42 |
References_xml | – volume: 90 start-page: 19 year: 2011 ident: 10.3349/ymj.2023.0466_ref17 publication-title: Medicine (Baltimore) doi: 10.1097/MD.0b013e318205a4c6 – volume: 60 start-page: 581 year: 2003 ident: 10.3349/ymj.2023.0466_ref10 publication-title: Microsc Res Tech doi: 10.1002/jemt.10300 – volume: 81 start-page: 315 year: 2022 ident: 10.3349/ymj.2023.0466_ref3 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2021-221795 – volume: 81 start-page: 321 year: 2022 ident: 10.3349/ymj.2023.0466_ref4 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2021-221796 – volume: 76 start-page: 1566 year: 2017 ident: 10.3349/ymj.2023.0466_ref26 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2016-210942 – volume: 2019 start-page: 2067353 year: 2019 ident: 10.3349/ymj.2023.0466_ref21 publication-title: Dis Markers doi: 10.1155/2019/2067353 – volume: 29 start-page: 943 year: 2019 ident: 10.3349/ymj.2023.0466_ref18 publication-title: Mod Rheumatol doi: 10.1080/14397595.2018.1551107 – volume: 61 start-page: 834 year: 2022 ident: 10.3349/ymj.2023.0466_ref11 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/keab413 – volume: 23 start-page: 42 year: 2022 ident: 10.3349/ymj.2023.0466_ref12 publication-title: BMC Immunol doi: 10.1186/s12865-022-00513-4 – volume: 5 start-page: 402 year: 2011 ident: 10.3349/ymj.2023.0466_ref19 publication-title: J Crohns Colitis doi: 10.1016/j.crohns.2011.03.011 – volume: 60 start-page: 10 year: 2019 ident: 10.3349/ymj.2023.0466_ref27 publication-title: Yonsei Med J doi: 10.3349/ymj.2019.60.1.10 – volume: 54 start-page: 3898 year: 2006 ident: 10.3349/ymj.2023.0466_ref28 publication-title: Arthritis Rheum doi: 10.1002/art.22217 – volume: 13 start-page: 931473 year: 2022 ident: 10.3349/ymj.2023.0466_ref9 publication-title: Front Immunol doi: 10.3389/fimmu.2022.931473 – volume: 72 start-page: 1 year: 2015 ident: 10.3349/ymj.2023.0466_ref23 publication-title: Vascul Pharmacol doi: 10.1016/j.vph.2015.06.011 – volume: 12 start-page: 2157 year: 2021 ident: 10.3349/ymj.2023.0466_ref30 publication-title: Adv Nutr doi: 10.1093/advances/nmab072 – volume: 310 start-page: 591 year: 2013 ident: 10.3349/ymj.2023.0466_ref25 publication-title: JAMA doi: 10.1001/jama.2013.13805 – volume: 64 start-page: 11 year: 2023 ident: 10.3349/ymj.2023.0466_ref15 publication-title: Yonsei Med J doi: 10.3349/ymj.2022.0435 – volume: 21 start-page: 847 year: 2015 ident: 10.3349/ymj.2023.0466_ref24 publication-title: Liver Transpl doi: 10.1002/lt.24129 – volume: 66 start-page: 222 year: 2007 ident: 10.3349/ymj.2023.0466_ref2 publication-title: Ann Rheum Dis doi: 10.1136/ard.2006.054593 – volume: 68 start-page: 1827 year: 2009 ident: 10.3349/ymj.2023.0466_ref16 publication-title: Ann Rheum Dis doi: 10.1136/ard.2008.101279 – volume: 63 start-page: 980 year: 2017 ident: 10.3349/ymj.2023.0466_ref22 publication-title: Clin Chem doi: 10.1373/clinchem.2016.264135 – volume: 27 start-page: 4922 year: 2022 ident: 10.3349/ymj.2023.0466_ref7 publication-title: Molecules doi: 10.3390/molecules27154922 – volume: 16 start-page: 111 year: 2015 ident: 10.3349/ymj.2023.0466_ref20 publication-title: BMC Musculoskelet Disord doi: 10.1186/s12891-015-0569-3 – volume: 1861 start-page: 354 year: 2017 ident: 10.3349/ymj.2023.0466_ref29 publication-title: Biochim Biophys Acta Gen Subj doi: 10.1016/j.bbagen.2016.11.040 – volume: 55 start-page: 230 year: 2017 ident: 10.3349/ymj.2023.0466_ref5 publication-title: Reumatologia doi: 10.5114/reum.2017.71638 – volume: 94 start-page: 55 year: 2013 ident: 10.3349/ymj.2023.0466_ref31 publication-title: J Leukoc Biol doi: 10.1189/jlb.1012519 – volume: 65 start-page: 1 year: 2013 ident: 10.3349/ymj.2023.0466_ref1 publication-title: Arthritis Rheum doi: 10.1002/art.37715 – volume: 42 start-page: 101958 year: 2021 ident: 10.3349/ymj.2023.0466_ref13 publication-title: Redox Biol doi: 10.1016/j.redox.2021.101958 – volume: 7 start-page: 12 year: 2009 ident: 10.3349/ymj.2023.0466_ref8 publication-title: Cell Commun Signal doi: 10.1186/1478-811X-7-12 – volume: 72 start-page: 1273 year: 2013 ident: 10.3349/ymj.2023.0466_ref6 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2013-203255 – volume: 62 start-page: 279 year: 2021 ident: 10.3349/ymj.2023.0466_ref14 publication-title: Yonsei Med J doi: 10.3349/ymj.2021.62.4.279 |
SSID | ssj0027102 |
Score | 2.3809493 |
Snippet | This study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein (EN-RAGE) and the... Purpose: This study aimed to investigate whether the serum extracellular newly identified receptor for advanced glycation end products binding protein... |
SourceID | nrf pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 651 |
SubjectTerms | Adult Aged Aged, 80 and over Biomarkers - blood Female Granulomatosis with Polyangiitis - blood Granulomatosis with Polyangiitis - diagnosis Granulomatosis with Polyangiitis - mortality Humans Male Microscopic Polyangiitis - blood Microscopic Polyangiitis - diagnosis Microscopic Polyangiitis - mortality Middle Aged Original Proportional Hazards Models Receptor for Advanced Glycation End Products - blood 의학일반 |
Title | Serum Soluble Receptors for Advanced Glycation End-Products May Predict Mortality in Microscopic Polyangiitis and Granulomatosis with Polyangiitis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39439169 https://www.proquest.com/docview/3119725149 https://pubmed.ncbi.nlm.nih.gov/PMC11519131 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003129791 |
Volume | 65 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Yonsei Medical Journal, 2024, 65(11), , pp.651-660 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3RbtMwFLXokKa9IAYDCqwyAvGWUsdOmjygaZo2BlJQH6jYm2U79haWOSNtJfIbfDH3JulGUZEiRUkcW_Fx7HOu7XsJeccmSoXh1AWJinkgmI0C9AkShM6A1J7kwHDRoJ99jc_n4stFdHHvUqivwMVWaYfxpOZ1Of71szmCH_4jKk4u0g_NzY8xRgEfg9aLB-QhDEox6rBMJPfai-FCnoOtr-yRXZ62O1DTjdFp4Gu3jXj-u37yrwHp7DF51DNJetxBv08eWP-E7Gb9XPlT8hu6gdUNRbuXLi0FfmhvMbQOBZpKj_upf_qpbDqjHT31eTDr_L8uaKYaOqsxryXN2soBtk4LTzNcwIdbWQpDZ1XZKH9ZoFskqjxkBgPfqqyABFcLuIU23o1EB2R-dvrt5DzoIzAEhk_TZcBywzQIjphrFSbGcB1aEym4tkCr4MhDbZkSwkZcTxX0umoSGmA9yqUuspY_Izu-8vYFocylhjvmIqFBJLlEaWAWSjhtXJ7HUzEk79c1L287RxsSBAqiJQEtiWhJRGtI3gIu8toUEl1j4_mykte1BAHwGV6BDiWKIbs3a9wk_DA4C6K8rVYLydtIa8AT0yF53uF4V-C6GQxJsoHwXQIscfOJL65ap9zArEH6cvbyv5m-InvwEaLbyPia7CzrlT0ERrPUIzKIgu-j1h4watvtHwYc-V0 |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+Soluble+Receptors+for+Advanced+Glycation+End-Products+May+Predict+Mortality+in+Microscopic+Polyangiitis+and+Granulomatosis+with+Polyangiitis&rft.jtitle=Yonsei+medical+journal&rft.au=Yoon%2C+Taejun&rft.au=Ahn%2C+Sung+Soo&rft.au=Ha%2C+Jang+Woo&rft.au=Ko%2C+Eunhee&rft.date=2024-11-01&rft.eissn=1976-2437&rft.volume=65&rft.issue=11&rft.spage=651&rft_id=info:doi/10.3349%2Fymj.2023.0466&rft_id=info%3Apmid%2F39439169&rft.externalDocID=39439169 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0513-5796&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0513-5796&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0513-5796&client=summon |